Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Res Treat. 2019;51(3):1144-1155. Published online November 20, 2018
Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
Citations
Citations to this article as recorded by
Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun BMC Women's Health.2024;[Epub] CrossRef
Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren Cancer Medicine.2023; 12(8): 10045. CrossRef
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park Clinical and Molecular Hepatology.2022; 28(1): 105. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives Stanislas Quesada, Michel Fabbro, Jérôme Solassol Cancers.2022; 14(4): 1098. CrossRef
Construction and validation of a transcription factors-based prognostic signature for ovarian cancer Qingyuan Cheng, Liman Li, Mingxia Yu Journal of Ovarian Research.2022;[Epub] CrossRef
Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim Frontiers in Microbiology.2022;[Epub] CrossRef
Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma Jiayi Li, Dongyan Cao Frontiers in Oncology.2022;[Epub] CrossRef
Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer Judan Zeng, Wenjiao Cao, Lihua Wang Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10. CrossRef
Sphingolipids as multifaceted mediators in ovarian cancer MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson Cellular Signalling.2021; 81: 109949. CrossRef
Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang Scientific Reports.2021;[Epub] CrossRef
Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park Journal of Medical Internet Research.2021; 23(4): e25852. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song Cancers.2021; 13(8): 1875. CrossRef
M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu Frontiers in Oncology.2021;[Epub] CrossRef
Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu Current Problems in Cancer.2020; 44(6): 100612. CrossRef
Can we predict who lives long with ovarian cancer? Michael A. Bookman Cancer.2019; 125(S24): 4578. CrossRef
Kyung Jin Eoh, Ji Eun Kim, Hyung Seok Park, Seung-Tae Lee, Ji Soo Park, Jung Woo Han, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Eun Ji Nam
Cancer Res Treat. 2018;50(3):917-925. Published online September 27, 2017
Purpose
Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer susceptibility genes and may represent a more efficient and less expensive approach than sequential testing. We assessed the frequency of germline mutations in individuals with epithelial ovarian cancer (EOC), using multi-gene panels and NGS.
Materials and Methods
Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were recruited consecutively, from March 2016 toDecember 2016.GermlineDNAwas sequenced using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic alteration using the panel, results were cross-validated using direct sequencing.
Results
Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight genes, including BRCA1 (n=21), BRCA2 (n=10), BRIP1 (n=1), CHEK2 (n=2), MSH2 (n=1), POLE (n=1), RAD51C (n=2), and RAD51D (n=2). Among 64 patients with a family history of cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had mutations in genes other than BRCA1/2, such as CHECK2, MSH2, POLE, and RAD51C. Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance.
Conclusion
Using the multi-gene panel test, we found that, of all patients included in our study, 32.5% had germline cancer-predisposing mutations. NGS was confirmed to substantially improve the detection rates of a wide spectrum of mutations in EOC patients compared with those obtained with the BRCA1/2 testing alone.
Citations
Citations to this article as recorded by
Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing Xiaojing Guan, Sheng Liao, Fenglan Zhang, Qianyuan Zhu, Hao Qiu, Lan Qin, Xiao Zhang BMC Cancer.2025;[Epub] CrossRef
Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand Chalermkiat Kansuttiviwat, Pongtawat Lertwilaiwittaya, Ekkapong Roothumnong, Panee Nakthong, Peerawat Dungort, Chutima Meesamarnpong, Warisara Tansa-Nga, Khontawan Pongsuktavorn, Supakit Wiboonthanasarn, Warunya Tititumjariya, Nannipa Phuphuripan, Chittap npj Genomic Medicine.2024;[Epub] CrossRef
Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer Zheng Feng, Siyu Chen, Na An, Zhihui Xiu, Xingzhu Ju, Xiaojun Chen, Rui Bi, Jie Wang, Shida Zhu, Xiaohua Wu, Hao Wen JCO Global Oncology.2024;[Epub] CrossRef
Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation Siddhartha Yadav, Fergus J. Couch, Susan M. Domchek Cold Spring Harbor Perspectives in Medicine.2024; 14(8): a041318. CrossRef
Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families Ava Kwong, Cecilia Yuen Sze Ho, Chun Hang Au, Sze Keong Tey, Edmond Shiu Kwan Ma Journal of Personalized Medicine.2024; 14(8): 866. CrossRef
Clinical Significance of PALB2 Pathogenic Germline Variant Min-Chae Kang, R.N., Jong Eun Park, Mi-Ae Jang, Dongju Won, Boyoung Park, Seeyoun Lee, Dong Ock Lee, Kum Hei Ryu, Yoon-Jung Chang, Sun-Young Kong Laboratory Medicine Online.2024; 14(4): 311. CrossRef
Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma Angel Chao, Chen-Yang Huang, Willie Yu, Chiao-Yun Lin, Hao Lin, An-Shine Chao, Cheng-Tao Lin, Hung-Hsueh Chou, Kuang-Gen Huang, Huei-Jean Huang, Ting-Chang Chang, Steven G. Rozen, Ren-Chin Wu, Chyong-Huey Lai BMC Cancer.2024;[Epub] CrossRef
Next-generation sequencing uncovers crucial mutated genes and potential therapeutic targets in ovarian cancer patients Tianjiao Zhao American Journal of Translational Research.2024; 16(10): 5990. CrossRef
The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study Dinh-Toi Chu, Mai Vu Ngoc Suong, Hue Vu Thi, Thuy-Duong Vu, Manh-Hung Nguyen, Vijai Singh Expert Review of Molecular Diagnostics.2023; 23(1): 53. CrossRef
Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2 Nandana D. Rao, Brian H. Shirts, Alvaro Galli PLOS ONE.2023; 18(2): e0278010. CrossRef
Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Serena Bertozzi, Ambrogio Londero, Anjeza Xholli, Guglielmo Azioni, Roberta Di Vora, Michele Paudice, Ines Bucimazza, Carla Cedolini, Angelo Cagnacci Journal of Clinical Medicine.2023; 12(4): 1422. CrossRef
Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence Roopak Murali, Vaishnavi Balasubramaniam, Satish Srinivas, Sandhya Sundaram, Ganesh Venkatraman, Sudha Warrier, Arun Dharmarajan, Rajesh Kumar Gandhirajan Metabolites.2023; 13(4): 560. CrossRef
Factors predictingBRCA1/2pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis Giovanni Innella, Lea Godino, Giulia Erini, Antonio De Leo, Donatella Santini, Anna Myriam Perrone, Pierandrea De Iaco, Claudio Zamagni, Daniela Turchetti Journal of Clinical Pathology.2023; 76(8): 510. CrossRef
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. Priyanka Narayan, Muhammad Danyal Ahsan, Emily M. Webster, Luiza Perez, Sarah R. Levi, Benedict Harvey, Isabel Wolfe, Shanice Beaumont, Jesse T. Brewer, Drew Siegel, Charlene Thomas, Paul Christos, Andy Hickner, Eloise Chapman-Davis, Evelyn Cantillo, Kevi Gynecologic Oncology.2023; 177: 72. CrossRef
Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition? Klara Horackova, Marketa Janatova, Petra Kleiblova, Zdenek Kleibl, Jana Soukupova International Journal of Molecular Sciences.2023; 24(23): 17020. CrossRef
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study Phuong L. Mai, Austin Miller, Amanda Black, Roni T. Falk, John F. Boggess, Katherine Tucker, Ashley R. Stuckey, Gustavo C. Rodriguez, Cheung Wong, Thomas T. Amatruda, Kelly J. Wilkinson, Susan C. Modesitt, S. Diane Yamada, Kristin L. Bixel, Gretchen E. Gl American Journal of Obstetrics and Gynecology.2022; 227(1): 61.e1. CrossRef
Hereditary gynecologic tumors and precision cancer medicine Chikako Ogawa, Akira Hirasawa, Naoyuki Ida, Keiichiro Nakamura, Hisashi Masuyama Journal of Obstetrics and Gynaecology Research.2022; 48(5): 1076. CrossRef
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim Cancer Genetics.2022; 266-267: 19. CrossRef
Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes Sidrah Shah, Alison Cheung, Mikolaj Kutka, Matin Sheriff, Stergios Boussios International Journal of Environmental Research and Public Health.2022; 19(13): 8113. CrossRef
Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome Tomoko Yoshihama, Akira Hirasawa, Kokichi Sugano, Teruhiko Yoshida, Mineko Ushiama, Arisa Ueki, Tomoko Akahane, Yoshiko Nanki, Kensuke Sakai, Takeshi Makabe, Wataru Yamagami, Nobuyuki Susumu, Kaori Kameyama, Kenjiro Kosaki, Daisuke Aoki International Cancer Conference Journal.2021; 10(1): 6. CrossRef
Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers Yoon Young Choi, Su-Jin Shin, Jae Eun Lee, Lisa Madlensky, Seung-Tae Lee, Ji Soo Park, Jeong-Hyeon Jo, Hyunki Kim, Daniela Nachmanson, Xiaojun Xu, Sung Hoon Noh, Jae-Ho Cheong, Olivier Harismendy Scientific Reports.2021;[Epub] CrossRef
Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A > T: a case report Mashu Futagawa, Hideki Yamamoto, Mariko Kochi, Yusaku Urakawa, Reimi Sogawa, Fumino Kato, Mika Okazawa-Sakai, Daisuke Ennishi, Katsunori Shinozaki, Hirofumi Inoue, Hiroyuki Yanai, Akira Hirasawa Hereditary Cancer in Clinical Practice.2021;[Epub] CrossRef
A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect Lesa M. Dawson, Kerri N. Smith, Salem Werdyani, Robyn Ndikumana, Cindy Penney, Louisa L. Wiede, Kendra L. Smith, Justin A. Pater, Andrée MacMillan, Jane Green, Sheila Drover, Terry‐Lynn Young, Darren D. O’Rielly Molecular Genetics & Genomic Medicine.2020;[Epub] CrossRef
Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer Yan You, Lei Li, Junliang Lu, Huanwen Wu, Jing Wang, Jie Gao, Ming Wu, Zhiyong Liang Frontiers in Oncology.2020;[Epub] CrossRef
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases Malwina Suszynska, Magdalena Ratajska, Piotr Kozlowski Journal of Ovarian Research.2020;[Epub] CrossRef
Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations Malwina Suszynska, Piotr Kozlowski Genes.2020; 11(7): 798. CrossRef
Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer Jin‐Sun Ryu, Hye‐Young Lee, Eun Hae Cho, Kyong‐Ah Yoon, Min‐Kyeong Kim, Jungnam Joo, Eun‐Sook Lee, Han‐Sung Kang, Seeyoun Lee, Dong Ock Lee, Myong Cheol Lim, Sun‐Young Kong Cancer Science.2020; 111(10): 3912. CrossRef
RAD51C and RAD51D in the hereditary breast and ovarian cancer syndrome Ana Isabel Sánchez Bermúdez, M.ª Desamparados Sarabia Meseguer, Verónica Guardiola Castillo, Francisco Ruiz Espejo, José Antonio Noguera Velasco Revista de Medicina de Laboratorio.2020;[Epub] CrossRef
Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes Jonas Henn, Isabel Spier, Ronja S. Adam, Stefanie Holzapfel, Siegfried Uhlhaas, Katrin Kayser, Guido Plotz, Sophia Peters, Stefan Aretz Hereditary Cancer in Clinical Practice.2019;[Epub] CrossRef
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes — Providing evidence of cancer predisposition genes Malwina Suszynska, Katarzyna Klonowska, Anna J. Jasinska, Piotr Kozlowski Gynecologic Oncology.2019; 153(2): 452. CrossRef
Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma Yu-Fa Su, Eing-Mei Tsai, Chih-Chieh Chen, Chun-Chieh Wu, Tze-Kiong Er Clinica Chimica Acta.2019; 494: 1. CrossRef
Hereditary ovarian cancers: state of the art Angela Toss, Eleonora Molinaro, Margaret Sammarini, Maria C. Del Savio, Laura Cortesi, Fabio Facchinetti, Giovanni Grandi Minerva Medica.2019;[Epub] CrossRef
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study Claudia Marchetti, Rossella De Leo, Angela Musella, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Pierluigi Benedetti Panici, Giovanni Scambia, Anna Fagotti Annals of Surgical Oncology.2018; 25(12): 3701. CrossRef
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski, Janusz Limon, Bartosz Wasag, Magdalena Ratajska Cancers.2018; 10(11): 442. CrossRef
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap Jeanna M McCuaig, Tracy L Stockley, Patricia Shaw, Michael Fung-Kee-Fung, Alon D Altman, James Bentley, Marcus Q Bernardini, Beatrice Cormier, Hal Hirte, Katharina Kieser, Andree MacMillan, Wendy S Meschino, Karen Panabaker, Renee Perrier, Diane Provenche Journal of Medical Genetics.2018; 55(9): 571. CrossRef
Eun Jin Heo, Young Jae Cho, William Chi Cho, Ji Eun Hong, Hye-Kyung Jeon, Doo-Yi Oh, Yoon-La Choi, Sang Yong Song, Jung-Joo Choi, Duk-Soo Bae, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Woong-Yang Park, Byoung-Gie Kim, Jeong-Won Lee
Cancer Res Treat. 2017;49(4):915-926. Published online January 4, 2017
Purpose
Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research.
Materials and Methods
We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues.
Results
Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023).
Conclusion
PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.
Citations
Citations to this article as recorded by
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research Minqi Liu, Xiaoping Yang Genes & Diseases.2025; 12(5): 101520. CrossRef
Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts Joseph J. Caumanns, Shang Li, Gert J. Meersma, Evelien W. Duiker, Ate G. J. van der Zee, G. Bea A. Wisman, Steven de Jong Scientific Reports.2025;[Epub] CrossRef
The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression Yoo-Young Lee, Ji-Yoon Ryu, Young-Jae Cho, Ju-Yeon Choi, Jung-Joo Choi, Chel Hun Choi, Jason K. Sa, Jae Ryoung Hwang, Jeong-Won Lee Cancer Cell International.2024;[Epub] CrossRef
Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan Journal of Clinical Medicine.2024; 13(9): 2718. CrossRef
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer Byumseok Koh, Ji-Yoon Ryu, Joseph J. Noh, Jae Ryoung Hwang, Jung-Joo Choi, Young-Jae Cho, Jiyoon Jang, Jeong Hyeon Jo, Kwangho Lee, Jeong-Won Lee Gynecologic Oncology.2024; 188: 60. CrossRef
Recent advances in lung cancer organoid (tumoroid) research (Review) Qiang Zhang, Mingyang Zhang Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Patient‐derived xenograft model in colorectal cancer basic and translational research Xiaofeng Liu, Zechang Xin, Kun Wang Animal Models and Experimental Medicine.2023; 6(1): 26. CrossRef
Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment Kenneth K. W. To, Ka M. Cheung, William C. S. Cho Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7217. CrossRef
Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer Chi-Son Chang, Ji-Yoon Ryu, June-Kuk Choi, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Joseph J. Noh, Chan Mi Lee, Ji Eun Won, Hee Dong Han, Jeong-Won Lee Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, Luiz Fernando Lopes Cancers.2023; 15(11): 2990. CrossRef
Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai Cancer Cell International.2023;[Epub] CrossRef
Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer 佳慧 吴 Advances in Clinical Medicine.2023; 13(06): 10496. CrossRef
Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Ju-Yeon Choi, Jung-Joo Choi, Jason K. Sa, Hyun-Soo Kim, Jeong-Won Lee Biomedicine & Pharmacotherapy.2023; 168: 115792. CrossRef
Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model Yukari Oda, Kaoru Niimi, Kosuke Yoshida, Satoshi Tamauchi, Akira Yokoi, Yuko Yasui, Yuki Nishiko, Mayu Shibata, Yusuke Shimizu, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Eiko Yamamoto, Hiroaki Kajiyama BMC Cancer.2023;[Epub] CrossRef
Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim Cancers.2022; 14(3): 829. CrossRef
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh Frontiers in Bioengineering and Biotechnology.2022;[Epub] CrossRef
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K. Sa, Jeong-Won Lee Gynecologic Oncology.2022; 165(2): 270. CrossRef
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee Clinical Cancer Research.2022; 28(17): 3850. CrossRef
Harnessing preclinical models for the interrogation of ovarian cancer Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review Lusine Sevinyan, Priyanka Gupta, Eirini Velliou, Thumuluru Kavitha Madhuri Cancers.2022; 14(22): 5628. CrossRef
A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report Yunke Huang, Jing Xu, Ke Li, Jing Wang, Yilin Dai, Yu Kang Cancer Management and Research.2021; Volume 13: 2849. CrossRef
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer Soo Young Jeong, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae-Ryoung Hwang, Binnari Kim, Yoo-Young Lee, Hyun-Soo Kim, Jeong-Won Lee Gynecologic Oncology.2021; 162(1): 173. CrossRef
Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies Paula Cunnea, Christina Fotopoulou, Jennifer Ploski, Fabian Trillsch, Sven Mahner, Mirjana Kessler Cancers.2021; 13(13): 3349. CrossRef
Methodological aspects of creation of patient-derived tumor xenografts A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov Kazan medical journal.2021; 102(5): 694. CrossRef
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis Jinseong Kim, Man Kyu Shim, Young-Jae Cho, Sangmin Jeon, Yujeong Moon, Jiwoong Choi, Jeongrae Kim, Jaewan Lee, Jeong-Won Lee, Kwangmeyung Kim Biomaterials.2021; 279: 121189. CrossRef
Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials Ana Karen Mendoza-Martinez, Daniela Loessner, Alvaro Mata, Helena S. Azevedo Cancers.2021; 13(22): 5745. CrossRef
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz Cancers.2021; 13(24): 6288. CrossRef
Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects Sharmin Seraj, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn Biochemical Pharmacology.2020; 171: 113735. CrossRef
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance Jiahao Shi, Yongyun Li, Renbing Jia, Xianqun Fan International Journal of Cancer.2020; 146(8): 2078. CrossRef
KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer Jinju Lee, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn Journal of Controlled Release.2020; 321: 184. CrossRef
A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma Tomoki Yamano, Shuji Kubo, Naohiro Tomita Cancer Medicine.2020; 9(10): 3337. CrossRef
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer E Sun Paik, Tae-Hyun Kim, Young Jae Cho, Jiyoon Ryu, Jung-Joo Choi, Yoo-Young Lee, Tae-Joong Kim, Chel-Hun Choi, Woo Young Kim, Jason K. Sa, Jin-Ku Lee, Byoung-Gie Kim, Duk-Soo Bae, Hee Dong Han, Hyung Jun Ahn, Jeong-Won Lee Scientific Reports.2020;[Epub] CrossRef
A Biobank of Colorectal Cancer Patient-Derived Xenografts Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki Cancers.2020; 12(9): 2340. CrossRef
Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, J Molecular Oncology.2020; 14(11): 2796. CrossRef
Human-Derived Model Systems in Gynecological Cancer Research Kadi Lõhmussaar, Matteo Boretto, Hans Clevers Trends in Cancer.2020; 6(12): 1031. CrossRef
Spontaneous and Induced Animal Models for Cancer Research Anca Onaciu, Raluca Munteanu, Vlad Cristian Munteanu, Diana Gulei, Lajos Raduly, Richard-Ionut Feder, Radu Pirlog, Atanas G. Atanasov, Schuyler S. Korban, Alexandru Irimie, Ioana Berindan-Neagoe Diagnostics.2020; 10(9): 660. CrossRef
Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee, Ji-Yoon Ryu, Jung-Joo Choi, Illju Bae, Zhaoyan Wu, Byoung-Gie Kim, Jae Ryoung Hwang, Jeong-Won Lee Pharmaceutics.2020; 12(10): 987. CrossRef
Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor E. Santo, Erwin R. Boghaert, Ana Félix, Catarina Brito Scientific Reports.2020;[Epub] CrossRef
Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer Jae Ryoung Hwang, Woo Young Kim, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Myeong-Sun Kim, Ji Hye Kim, E. Sun Paik, Yoo-Young Lee, Hee-Dong Han, Jeong-Won Lee Cell Death & Disease.2020;[Epub] CrossRef
Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim Translational Oncology.2019; 12(2): 269. CrossRef
Platinum Resistance in Ovarian Cancer: Role of DNA Repair Giovanna Damia, Massimo Broggini Cancers.2019; 11(1): 119. CrossRef
Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062. CrossRef
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya Cells.2019; 8(8): 889. CrossRef
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research Akira Inoue, Angela K. Deem, Scott Kopetz, Timothy P. Heffernan, Giulio F. Draetta, Alessandro Carugo Cancers.2019; 11(9): 1321. CrossRef
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers Jason K. Sa, Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Jihye Kim, Myeong Seon Kim, E. Sun Paik, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yeri Lee, Nam-Gu Her, Yong Jae Shin, Hee Jin Cho, Genome Biology.2019;[Epub] CrossRef
The latest animal models of ovarian cancer for novel drug discovery Elizabeth Magnotti, Wayne A. Marasco Expert Opinion on Drug Discovery.2018; 13(3): 249. CrossRef
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi Medicines.2018; 5(1): 16. CrossRef
NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye Caiqin Zhang, Yong Zhao, Ningning Zhao, Dengxu Tan, He Zhang, Xue Chen, Hai Zhang, Jiaze An, Changhong Shi, Mengbin Li Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam Cancer Research and Treatment.2018; 50(3): 956. CrossRef
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung, Young-Jae Cho, Hyung Jun Ahn, Byung Cheol Shin, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong-Min Park Cancer Research.2018; 78(21): 6247. CrossRef
Purpose
The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type).
Materials and Methods
We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status.
Results
Thirty-seven (37/116, 31.9%) BRCA1/2 mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively).
Conclusion
Patientswith BRCA1/2 mutation had longer OS than thosewith BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.
Citations
Citations to this article as recorded by
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer Pierre-Emmanuel Colombo, Christophe Taoum, Michel Fabbro, Stanislas Quesada, Philippe Rouanet, Isabelle Ray-Coquard Critical Reviews in Oncology/Hematology.2024; 202: 104469. CrossRef
The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study Dinh-Toi Chu, Mai Vu Ngoc Suong, Hue Vu Thi, Thuy-Duong Vu, Manh-Hung Nguyen, Vijai Singh Expert Review of Molecular Diagnostics.2023; 23(1): 53. CrossRef
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors Lucia Musacchio, Serena Boccia, Claudia Marchetti, Angelo Minucci, Floriana Camarda, Chiara Cassani, Jole Ventriglia, Vanda Salutari, Viola Ghizzoni, Elena Giudice, Maria resa Te Perri, Maria Vittoria Carbone, Caterina Ricci, Sandro Pignata, Anna Fagotti, International Journal of Gynecological Cancer.2023; 33(6): 922. CrossRef
Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line models Garrett M. Draper, Daniel J. Panken, David A. Largaespada Genes, Chromosomes and Cancer.2023; 62(9): 493. CrossRef
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma Brooke B. Bartow, Gene P. Siegal, Ceren Yalniz, Ahmed M. Elkhanany, Lei Huo, Qingqing Ding, Aysegul A. Sahin, Hua Guo, Cristina Magi-Galluzzi, Shuko Harada, Xiao Huang Cancers.2023; 15(9): 2524. CrossRef
Factors predictingBRCA1/2pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis Giovanni Innella, Lea Godino, Giulia Erini, Antonio De Leo, Donatella Santini, Anna Myriam Perrone, Pierandrea De Iaco, Claudio Zamagni, Daniela Turchetti Journal of Clinical Pathology.2023; 76(8): 510. CrossRef
Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis Yazhuo Wang, Na Li, Yanan Ren, Jing Zhao Journal of Obstetrics and Gynaecology Research.2022; 48(9): 2270. CrossRef
Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge Cláudia Caeiro, Inês Leão, Inês Oliveira, Isabel Sousa, Teresa André Advances in Therapy.2022; 39(11): 5289. CrossRef
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients Giorgia Gurioli, Gianluca Tedaldi, Alberto Farolfi, Elisabetta Petracci, Claudia Casanova, Giuseppe Comerci, Rita Danesi, Valentina Arcangeli, Mila Ravegnani, Daniele Calistri, Valentina Zampiga, Ilaria Cangini, Eugenio Fonzi, Alessandra Virga, Davide Tas International Journal of Molecular Sciences.2022; 23(24): 15789. CrossRef
Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis Shira Peleg Hasson, Dov Hershkovitz, Lyri Adar, Miriam Brezis, Eliya Shachar, Rona Aks, Lee Galmor, Yuval Raviv, Shira Ben Neriah, Ofer Merimsky, Edmond Sabo, Ido Wolf, Tamar Safra Cancers.2022; 15(1): 218. CrossRef
Current update on malignant epithelial ovarian tumors Sherif B. Elsherif, Priya R. Bhosale, Chandana Lall, Christine O. Menias, Malak Itani, Kristina A. Butler, Dhakshinamoorthy Ganeshan Abdominal Radiology.2021; 46(6): 2264. CrossRef
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer Kyung Jin Eoh, Hye Min Kim, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam BMC Cancer.2020;[Epub] CrossRef
Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma Haijie Hu, Yayun Zhu, Ning Pu, Richard A. Burkhart, William Burns, Daniel Laheru, Lei Zheng, Jin He, Michael G. Goggins, Jun Yu Journal of the American College of Surgeons.2020; 231(5): 527. CrossRef
Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers Hyeong In Ha, Jin-Sun Ryu, Hyoeun Shim, Sun-Young Kong, Myong Cheol Lim Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts Anastasis Oulas, George Minadakis, Margarita Zachariou, George M. Spyrou Scientific Reports.2019;[Epub] CrossRef
Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song Journal of Ovarian Research.2019;[Epub] CrossRef
Clinical significance of variants of unknown significances in BRCA genes Min Chul Choi Journal of Gynecologic Oncology.2019;[Epub] CrossRef
DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies Mohammad Mirza-Aghazadeh-Attari, Caspian Ostadian, Amir Ata Saei, Ainaz Mihanfar, Saber Ghazizadeh Darband, Shirin Sadighparvar, Mojtaba Kaviani, Hossein Samadi Kafil, Bahman Yousefi, Maryam Majidinia DNA Repair.2019; 80: 59. CrossRef
Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review Byung Su Kwon, Jung Mi Byun, Hyun Joo Lee, Dae Hoon Jeong, Tae Hwa Lee, Kyung-Hwa Shin, Dong Soo Suh, Ki Hyung Kim Cancer Research and Treatment.2019; 51(3): 941. CrossRef
Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea Jun Hyeong Seo, Soo Young Jeong, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi Obstetrics & Gynecology Science.2019; 62(6): 411. CrossRef
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer Min Chul Choi, Ja-Hyun Jang, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Je Ho Lee International Journal of Gynecological Cancer.2018; 28(2): 308. CrossRef
Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube Min Chul Choi, Jin-Sik Bae, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Ji-Ho Kim, Ki-Chan Lee, Sunghoon Lee, Je Ho Lee Journal of Gynecologic Oncology.2018;[Epub] CrossRef
Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2 Kyung Jin Eoh, Ji Eun Kim, Hyung Seok Park, Seung-Tae Lee, Ji Soo Park, Jung Woo Han, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Eun Ji Nam Cancer Research and Treatment.2018; 50(3): 917. CrossRef
ATL Xinxin Zhu, Ling Zhao, Jinghe Lang International Journal of Gynecologic Cancer.2018; 28(8): 1514. CrossRef
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic‐related mutations in BRCA1 associated with an increased risk of ovarian cancer Tingyan Shi, Pan Wang, Caixia Xie, Sheng Yin, Di Shi, Congchong Wei, Wenbin Tang, Rong Jiang, Xi Cheng, Qingyi Wei, Qing Wang, Rongyu Zang International Journal of Cancer.2017; 140(9): 2051. CrossRef
Role and clinical application of next-generation sequencing (NGS) for ovarian cancer Myong Cheol Lim, Leslie M. Randall Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Purpose
The aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment for patients with primary mucinous epithelial ovarian cancer.
Materials and Methods
A retrospective study of patients with mucinous ovarian cancer between 1991 and 2010 was performed. The demographics and survival outcomes were compared between patients who underwent fertility-sparing surgery and those who underwent radical surgery.
Results
A total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan- Meier curve and the log rank test showed no difference in either recurrence-free survival (p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore, there was no significant difference in recurrence-free survival (p=0.126) or disease-specific survival (p=0.377) between the two groups, even when the analysis was limited to women below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).
Conclusion
Fertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be a safe option and one not associated with an increase in recurrence or mortality.
Citations
Citations to this article as recorded by
A Complex Case: Solid Unilateral Ovarian Mucinous Carcinoma Masquerading as Leiomyosarcoma in Postmenopausal Women Naina Kumar, Immanuel Pradeep, Mishu Mangla, Annapurna Srirambhatla Current Womens Health Reviews.2025;[Epub] CrossRef
Prognosis of stage-I ovarian mucinous tumors according to expansile and infiltrative types Malek Bouhani, Stéphanie Schérier, Catherine Genestie, Mojgan Devouassoux-Shisheboran, Amandine Maulard, Francois Zaccarini, Alexandra Leary, Patricia Pautier, Philippe Morice, Sébastien Gouy International Journal of Gynecological Cancer.2025; : 101641. CrossRef
Controversies in the management of mucinous ovarian tumors Félix Blanc-Durand, Alexandra Leary International Journal of Gynecological Cancer.2025; 35(3): 101679. CrossRef
Fertility-sparing surgery upon reproductive and oncologic results in ovarian cancer patients stage I (FIGO): a systematic review Stylianos Sergios Chatziioannou, Varvara Papasideri, Chrisostomos Sofoudis Archives of Gynecology and Obstetrics.2025;[Epub] CrossRef
Safety of fertility-sparing surgery in young women with stage I endometrioid epithelial and mucinous ovarian cancer: A population-based analysis Jing Li, Huimin Qiao, Yunyun Liu, Chunxian Huang, Aoshuang Cheng, Zhongqiu Lin, Lijuan Wang, Huaiwu Lu European Journal of Surgical Oncology.2024; 50(1): 107276. CrossRef
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, Yeh Chen Lee, Clare Scott, Pearly Khaw, Prue Allan, Claire Davies, John Andrews, Michelle Wilson, Janine M Lombard, Michelle Harrison, Heshani Nesfield, Anna DeFazio, Tarek Meniawy, Kylie L Gorringe Australian and New Zealand Journal of Obstetrics and Gynaecology.2024; 64(4): 319. CrossRef
Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan Syed Abdul Mannan Hamdani, Musa Azhar, Abdul Wahab, Tahira Yasmeen, Neelam Siddiqui South Asian Journal of Cancer.2023; 12(01): 081. CrossRef
Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer Fulvio Borella, Marco Mitidieri, Stefano Cosma, Chiara Benedetto, Luca Bertero, Stefano Fucina, Isabelle Ray-Coquard, Annalisa Carapezzi, Domenico Ferraioli Cancers.2023; 15(4): 1172. CrossRef
Safety of fertility sparing management in invasive mucinous ovarian carcinoma Soyoun Rachel Kim, Ainhoa Madariaga, Liat Hogen, Danielle Vicus, Allan Covens, Carlos Parra-Herran, Stephanie Lheureux, Lilian T. Gien Gynecologic Oncology.2023; 174: 129. CrossRef
Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas Olivia Craig, Abhimanyu Nigam, Genevieve V. Dall, Kylie Gorringe Cold Spring Harbor Perspectives in Medicine.2023; 13(9): a038190. CrossRef
Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma Wei Lin, Dongyan Cao, Xiaohua Shi, Yan You, Jiaxin Yang, Keng Shen Frontiers in Oncology.2022;[Epub] CrossRef
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted? Marc D. Algera, Willemien J. van Driel, Koen K. van de Vijver, Roy F.P.M. Kruitwagen, Christianne A.R. Lok Current Opinion in Oncology.2022; 34(5): 497. CrossRef
Primary mucinous ovarian cancer: options for surgery and chemotherapy Katherine C Kurnit, Michael Frumovitz International Journal of Gynecological Cancer.2022; 32(11): 1455. CrossRef
Outcomes after Fertility-sparing Surgery for Women with Ovarian Cancer: A Systematic Review of the Literature Alexandra Bercow, Roni Nitecki, Paula C. Brady, J.Alejandro Rauh-Hain Journal of Minimally Invasive Gynecology.2021; 28(3): 527. CrossRef
Fertility preserving surgery in carcinoma ovary: a single institution experience T. Subramanyeshwar Rao, KVVN Raju, Vikas Gupta, R. Rajagopalan Iyer Indian Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review Teska Schuurman, Sanne Zilver, Sanne Samuels, Winnie Schats, Frédéric Amant, Nienke van Trommel, Christianne Lok Cancers.2021; 13(5): 1008. CrossRef
Fertility preservation in rare ovarian tumors Anca Chelariu-Raicu, Lauren P Cobb, David M Gershenson International Journal of Gynecological Cancer.2021; 31(3): 432. CrossRef
Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma Dimitrios Nasioudis, Lakeisha Mulugeta-Gordon, Erin McMinn, Maureen Byrne, Emily M Ko, Lori Cory, Ashley F Haggerty, Nawar A Latif International Journal of Gynecological Cancer.2021; 31(3): 480. CrossRef
Fertility-Sparing Surgery for Ovarian Cancer Geoffroy Canlorbe, Nathalie Chabbert-Buffet, Catherine Uzan Journal of Clinical Medicine.2021; 10(18): 4235. CrossRef
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata Cancer Treatment Reviews.2021; 101: 102298. CrossRef
Options for the Treatment of Mucinous Ovarian Carcinoma Olivia Craig, Carolina Salazar, Kylie L. Gorringe Current Treatment Options in Oncology.2021;[Epub] CrossRef
Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival Denghua Liu, Jing Cai, Aiwei Gao, Zehua Wang, Liqiong Cai BMC Cancer.2020;[Epub] CrossRef
Fertility‐sparing treatment for early‐stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives Rachel S. Mandelbaum, Maximilian Klar, Tsuyoshi Takiuchi, Liat Bainvoll, Shinya Matsuzaki, Richard J. Paulson, Koji Matsuo Journal of Obstetrics and Gynaecology Research.2020; 46(8): 1263. CrossRef
Impact of uterus‐preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi‐institutional study with propensity score‐weighted analysis Masato Yoshihara, Hiroaki Kajiyama, Satoshi Tamauchi, Shohei Iyoshi, Akira Yokoi, Shiro Suzuki, Michiyasu Kawai, Tetsuro Nagasaka, Kunihiko Takahashi, Shigeyuki Matsui, Fumitaka Kikkawa International Journal of Gynecology & Obstetrics.2020; 150(2): 177. CrossRef
Tumeurs épithéliales de l’ovaire : préservation de la fertilité. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épi C. Uzan, B. Courbiere, N. Chabbert-Buffet Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 180. CrossRef
Mucinous Ovarian Carcinoma Dan L. Longo, Philippe Morice, Sebastien Gouy, Alexandra Leary New England Journal of Medicine.2019; 380(13): 1256. CrossRef
Early stage mucinous ovarian cancer: A review Erin K. Crane, Jubilee Brown Gynecologic Oncology.2018; 149(3): 598. CrossRef
Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers Sebastien Gouy, Marine Saidani, Amandine Maulard, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice The Oncologist.2018; 23(3): 324. CrossRef
Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers Ignacio Zapardiel, Maria Cruz, Maria D. Diestro, Antonio Requena, Juan A. Garcia-Velasco Human Reproduction Update.2016; 22(3): 281. CrossRef
Fertility-Sparing Surgery in Epithelial Ovarian Cancer Enrica Bentivegna, Philippe Morice, Catherine Uzan, Sebastien Gouy Future Oncology.2016; 12(3): 389. CrossRef
Mucinous ovarian cancer: A therapeutic review Wen Xu, Jack Rush, Kirsty Rickett, Jermaine I.G. Coward Critical Reviews in Oncology/Hematology.2016; 102: 26. CrossRef
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer Robert Fruscio, Lorenzo Ceppi, Silvia Corso, Francesca Galli, Tiziana Dell'Anna, Federica Dell'Orto, Daniela Giuliani, Annalisa Garbi, Stefania Chiari, Costantino Mangioni, Rodolfo Milani, Irene Floriani, Nicoletta Colombo, Cristina Maria Bonazzi British Journal of Cancer.2016; 115(6): 641. CrossRef
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues E. Bentivegna, S. Gouy, A. Maulard, P. Pautier, A. Leary, N. Colombo, P. Morice Annals of Oncology.2016; 27(11): 1994. CrossRef
Central nervous system (CNS) toxicity has been reported in approximately 10-30% of patients receiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse reaction in these patients, and although usually transient and reversible, may cause persistent neurological dysfunction or death. Clinical features range from fatigue and confusion to coma and death. Although methylene blue can be used to treat ifosfamide-induced neurotoxicity, including encephalopathy, its mechanism of action remains poorly defined. We describe here two patients with recurrent epithelial ovarian cancer who experienced fatal encephalopathy following ifosfamide/mesna treatment.
Citations
Citations to this article as recorded by
New metabolic insights into the mechanism of ifosfamide encephalopathy Diren Beyoğlu, Paul Hamberg, Nikki S. IJzerman, Ron H.J. Mathijssen, Jeffrey R. Idle Biomedicine & Pharmacotherapy.2025; 182: 117773. CrossRef
Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity Ambika Menon, Chidiebele A. Enunwa, William L. Read, Kyle P. James Case Reports in Oncology.2024; 17(1): 202. CrossRef
Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy Ragini D. Singh, Avadhesh Avadhesh, Gaurav Sharma, Sagar Dholariya, Rima B. Shah, Bela Goyal, Subash Chandra Gupta Antioxidants & Redox Signaling.2023; 38(10-12): 853. CrossRef
Ifosfamide - History, efficacy, toxicity and encephalopathy Jeffrey R. Idle, Diren Beyoğlu Pharmacology & Therapeutics.2023; 243: 108366. CrossRef
A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant Tomomi Sano, Nokitaka Setsu, Eisuke Kobayashi, Akira Kawai YAKUGAKU ZASSHI.2023; 143(6): 541. CrossRef
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies Ali Zarrabi, David Perrin, Mahboubeh Kavoosi, Micah Sommer, Serap Sezen, Parvaneh Mehrbod, Bhavya Bhushan, Filip Machaj, Jakub Rosik, Philip Kawalec, Saba Afifi, Seyed Mohammadreza Bolandi, Peiman Koleini, Mohsen Taheri, Tayyebeh Madrakian, Marek J. Łos, Cancers.2023; 15(21): 5269. CrossRef
Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case Eren Müngen, İnci Yaman Bajin, Sibel Öz, Ceren Günbey, Banu Anlar, Burca Aydin Journal of Pediatric Hematology/Oncology.2022; 44(7): 402. CrossRef
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality? Halima Abahssain, Badreddine Moukafih, Hajar Essangri, Hind Mrabti, Bouchra Meddah, Fadila Guessous, Fatima Zahra Fadhil, Amine Souadka, Hassan Errihani Journal of Oncology Pharmacy Practice.2021; 27(1): 143. CrossRef
Effect of Berberis vulgaris L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity Shazia Ilyas, Raheela Tabasum, Ali Iftikhar, Mamoona Nazir, Amina Hussain, Aroosha Hussain, Muhammad Sajjad Ali, Farooq Saleem, Uzma Saleem, Matheus Froeyen, Iskandar Abdullah, Muhammad Usman Mirza, Sarfraz Ahmad Scientific Reports.2021;[Epub] CrossRef
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer Eda Ataseven, Şebnem Önen Göktepe, Mehmet Kantar Journal of Oncology Pharmacy Practice.2021; 27(8): 2018. CrossRef
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies Claudia Pellacani, Georgios Eleftheriou Advances in Medical Sciences.2020; 65(2): 265. CrossRef
Delayed Ifosfamide Neurotoxicity Jill Yeager, Alina Basnet American Journal of Therapeutics.2020; 27(6): e613. CrossRef
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy Aaron M. Gusdon, Rachna Malani, Xi Chen Journal of Clinical Neurophysiology.2019; 36(2): 150. CrossRef
Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome Natacha Stern, Ilyes Sakji, Anne-Sophie Defachelles, Cyril Lervat, Thomas Ryckewaert, Guillaume Marliot, Charlotte Peugniez, Dominique Deplanque, Nicolas Penel Bulletin du Cancer.2017; 104(3): 208. CrossRef
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis Yin Lo, Li-Jiuan Shen, Wen-Hwei Chen, Yaa-Hui Dong, Fe-Lin Lin Wu Journal of the Formosan Medical Association.2016; 115(9): 744. CrossRef
The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide Martin S. Highley, Guido Momerency, Diane Sawyers, Ernst A. De Bruijn, Hans Prenen, Gunther Guetens, Gert De Boeck, Allan T. Van Oosterom, Janine L. Mansi, Peter R. Blake, Tim Mant, Robert A.A. Maes, Peter G. Harper Journal of Analytical Oncology.2015;[Epub] CrossRef
Ifosfamide related encephalopathy: The need for a timely EEG evaluation Anteneh M. Feyissa, Sudhakar Tummala Journal of the Neurological Sciences.2014; 336(1-2): 109. CrossRef
PharmGKB summary Daniella Lowenberg, Caroline F. Thorn, Zeruesenay Desta, David A. Flockhart, Russ B. Altman, Teri E. Klein Pharmacogenetics and Genomics.2014; 24(2): 133. CrossRef
Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert Case Reports in Oncology.2014; 7(3): 669. CrossRef